Glenmark launches Akynzeo IV in India
It's the first fixed IV anti-emetic combination for the prevention of chemotherapy-induced nausea and vomiting
Glenmark Pharma has launched an IV injection formulation, Akynzeo, for the prevention of Chemotherapy-Induced Nausea and Vomiting (CINV), under an exclusive licensing agreement with Helsinn, a Swiss biopharma group company, according to a statement from Glenmark Pharma.
The statement said that Akynzeo IV is a fixed-dose combination of fosnetupitant (235 mg) and palonosetron (0.25 mg), and is available as a ready-to-dilute IV injection. It is administered as a single infusion 30 minutes prior to the start of each chemotherapy cycle that helps in preventing both, acute and delayed phases of CINV. The drug is already being marketed in the EU, the US and Australia.